[1] Vangangelt KMH, Green AR, Heemskerk IMF, et al. The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. International journal of cancer. 2020;146:2296–2304.
[2] Vangangelt KMH, Tollenaar LSA, van Pelt GW, et al. The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients. International journal of cancer. 2018;143:3194–3200.
[3] Xu Q, Yuan J-P, Chen Y-Y, et al. Prognostic Significance of the Tumor-Stromal Ratio in Invasive Breast Cancer and a Proposal of a New Ts-TNM Staging System. Journal of oncology. 2020;2020:9050631.
[4] Hagenaars SC, de Groot S, Cohen D, et al. Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. International journal of cancer. 2021;149:1181–1188.
[5] Mallya V, Singh V, Kaur N, et al. Does tumor stroma ratio of breast cancer trucut biopsy determine response to neoadjuvant therapy? Indian journal of pathology & microbiology. 2020;63:S113–S116.
[6] Vangangelt KMH, van Pelt GW, Engels CC, et al. Prognostic value of tumor-stroma ratio combined with the immune status of tumors in invasive breast carcinoma. Breast cancer research and treatment. 2018;168:601–612.
[7] Dekker TJA, van de Velde CJH, van Pelt GW, et al. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast cancer research and treatment. 2013;139:371–379.
[8] Wang M, He X, Chang Y, et al. A sensitivity and specificity comparison of fine needle aspiration cytology and core needle biopsy in evaluation of suspicious breast lesions: A systematic review and meta-analysis. Breast (Edinburgh, Scotland). 2017;31:157–166.
[9] Koo TK, Li MY. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. Journal of chiropractic medicine. 2016;15:155–163.
[10] Odate T, Le M-K, Kawai M, et al. Tumor-infiltrating lymphocytes in breast FNA biopsy cytology: a predictor of tumor-infiltrating lymphocytes in histologic evaluation. Cancer cytopathology. 2022;
[11] Akoglu H. User’s guide to correlation coefficients. Turkish journal of emergency medicine. 2018;18:91–93.
[12] Mesker WE, Junggeburt JMC, Szuhai K, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cellular oncology : the official journal of the International Society for Cellular Oncology. 2007;29:387–398.
[13] Eriksen AC, Sørensen FB, Lindebjerg J, et al. The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. International journal of colorectal disease. 2018;33:1115–1124.
[14] Gao J, Shen Z, Deng Z, et al. Impact of Tumor-Stroma Ratio on the Prognosis of Colorectal Cancer: A Systematic Review. Frontiers in oncology. 2021. p. 738080.
[15] Bever KM, Sugar EA, Bigelow E, et al. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2015;17:292–298.
[16] Wu J, Liang C, Chen M, et al. Association between tumor-stroma ratio and prognosis in solid tumor patients: a systematic review and meta-analysis. Oncotarget. 2016;7:68954–68965.
[17] Liu J, Li C, Huang K, et al. A classification based on tumor-stroma ratio and tumor budding for patients with muscle-invasive bladder cancer. Expert review of anticancer therapy. 2021;1–8.
[18] Park H, Lee Y, Lee H, et al. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2017;39:1010428317718403.
[19] Huang H, Brekken RA. Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. American journal of physiology Cell physiology. 2020;319:C233–C243.
[20] He R, Li D, Liu B, et al. The prognostic value of tumor-stromal ratio combined with TNM staging system in esophagus squamous cell carcinoma. Journal of Cancer. 2021;12:1105–1114.
[21] Peng C, Liu J, Yang G, et al. The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system. Journal of gastroenterology. 2018;53:606–617.
[22] Karpathiou G, Vieville M, Gavid M, et al. Prognostic significance of tumor budding, tumor-stroma ratio, cell nests size, and stroma type in laryngeal and pharyngeal squamous cell carcinomas. Head & neck. 2019;41:1918–1927.
[23] Hansen TF, Kjær-Frifeldt S, Lindebjerg J, et al. Tumor-stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. Acta oncologica (Stockholm, Sweden). 2018;57:528–533.
[24] Bello IO, Wennerstrand PM, Suleymanova I, et al. Biopsy quality is essential for preoperative prognostication in oral tongue cancer. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2021;129:118–127.
[25] Liang Y, Zhu Y, Lin H, et al. The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study. BMC cancer. 2021;21:729.
[26] Vangangelt KMH, Kramer CJH, Bastiaannet E, et al. The intra-tumoural stroma in patients with breast cancer increases with age. Breast cancer research and treatment. 2020;179:37–45.
[27] Chung W, Eum HH, Lee H-O, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nature communications. 2017;8:15081.
[28] Roulot A, Héquet D, Guinebretière J-M, et al. Tumoral heterogeneity of breast cancer. Annales de biologie clinique. 2016;74:653–660.
[29] Bareche Y, Buisseret L, Gruosso T, et al. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. Journal of the National Cancer Institute. 2020;112:708–719.
[30] Tamura N, Hasebe T, Okada N, et al. Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. Cancer science. 2009;100:1823–1833.
[31] Dekker TJA, Charehbili A, Smit VTHBM, et al. Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. Molecular oncology. 2015;9:1120–1128.
[32] Du Y, Zhang R, Zargari A, et al. Classification of Tumor Epithelium and Stroma by Exploiting Image Features Learned by Deep Convolutional Neural Networks. Annals of biomedical engineering. 2018;46:1988–1999.
[33] Ko ES, Han B-K, Kim RB, et al. Apparent diffusion coefficient in estrogen receptor-positive invasive ductal breast carcinoma: correlations with tumor-stroma ratio. Radiology. 2014;271:30–37.
[34] Yamaguchi K, Hara Y, Kitano I, et al. Tumor-stromal ratio (TSR) of invasive breast cancer: correlation with multi-parametric breast MRI findings. The British journal of radiology. 2019;92:20181032.
[35] Li Y, Wang Z, Chen F, et al. Intravoxel incoherent motion diffusion-weighted MRI in patients with breast cancer: Correlation with tumor stroma characteristics. European journal of radiology. 2019;120:108686.
[36] Cha YJ, Ahn SG, Bae SJ, et al. Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis. Breast cancer research and treatment. 2018;171:295–302.